Denemek ALTIN - Özgür
Boston Scientific expands operations in Malaysia
BioSpectrum Asia
|December 2022
Boston Scientific Corporation, a global leader in medical device technology, has unveiled a new expansion of its operations in Batu Kawan, Penang, Malaysia.
-
Bu hikaye BioSpectrum Asia dergisinin December 2022 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
BioSpectrum Asia'den DAHA FAZLA HİKAYE
BioSpectrum Asia
Leadgene Biosolutions expands product portfolio for metabolic research
Leadgene Biosolutions has announced the expansion of its product portfolio following its strategic integration into Leadgene Biomedical.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Korea, Philippines to develop nextgeneration tuberculosis diagnosis
The Korea National Institute of Health (NIH), under the Korea Disease Control and Prevention Agency (KDCA) is entering into a research agreement with the Research Institute for Tropical Medicine (RITM) of the Philippines to initiate an international collaborative research project aimed at developing next-generation tuberculosis (TB) diagnostic technologies.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Australia and Indonesia achieve WHO Listed Authority status in medical products regulation
The World Health Organization (WHO) has formally recognised the regulatory authorities for medical products of Australia and Indonesia as WHO Listed Authorities (WLAs), an achievement that underscores growing global confidence in regulatory systems across diverse regions and income settings.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries
Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Aevice Health announces expansion into Australian market
AeviceMD Monitoring System, a non-invasive wearable respiratory monitoring solution developed by Singapore-based Aevice Health, has been included in the Australian Register of Therapeutic Goods (ARTG) as a Class IIa medical device.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Insilico Medicine lists on Hong Kong Stock Exchange, exhibiting largest Hong Kong biotech IPO
Insilico Medicine, a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Australia provides cheaper medicines for inflammatory & rare liver disease and MS
Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple sclerosis (MS) will pay less for newly Pharmaceutical Benefits Scheme (PBS) listed medicines, as directed by the Australian Government.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Valneva and Serum Institute of India discontinue Chikungunya vaccine license agreement
France-based Valneva SE, a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company, have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Santhera licenses AGAMREE to Nxera Pharma in $205 M Asia-Pacific deal
Swiss firm Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK for the development, manufacturing and commercialisation of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia and New Zealand.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
AdCella and Shanghai Cell Therapy Group launch global collaboration for cancer therapy
Australia-based AdAlta, developer of next generation cell and protein therapeutic products, and its cellular immunotherapy subsidiary, AdCella have signed a major development agreement with Shanghai Cell Therapy Group (SHcell) to bring an innovative cancer treatment, BZDS1901, to markets outside China.
1 min
BioSpectrum Asia Feb 2026
Translate
Change font size